Compounds > glycyl-leucyl-phenylalanine

Page last updated: 2024-12-07

glycyl-leucyl-phenylalanine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

glycyl-leucyl-phenylalanine: an immunostimulatory peptide; RN given refer to all (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	128287
CHEMBL ID	209670
CHEBI ID	163814
SCHEMBL ID	4281374
MeSH ID	M0173039

Synonyms (17)

Synonym
glycyl-leucyl-phenylalanine
bdbm50188525
(2s)-2-[[(2s)-2-[(2-aminoacetyl)amino]-4-methylpentanoyl]amino]-3-phenylpropanoic acid
CHEBI:163814
gly-leu-phe
103213-38-3
CHEMBL209670 ,
l-phenylalanine, n-(n-glycyl-l-leucyl)-
l-gly-l-leu-l-phe
SCHEMBL4281374
h-gly-leu-phe-oh
(s)-2-((s)-2-(2-aminoacetamido)-4-methylpentanamido)-3-phenylpropanoic acid
mfcd00057838
glycyl-l-leucyl-l-phenylalanine
(2s)-2-[[(2s)-2-[(2-azaniumylacetyl)amino]-4-methylpentanoyl]amino]-3-phenylpropanoate
n-{2-[(2-amino-1-hydroxyethylidene)amino]-1-hydroxy-4-methylpentylidene}phenylalanine
DTXSID60908255

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
oligopeptide	A peptide containing a relatively small number of amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Solute carrier family 15 member 1	Homo sapiens (human)	IC50 (µMol)	980.0000	0.1800	0.1900	0.2000	AID266249
Mu-type opioid receptor	Cavia porcellus (domestic guinea pig)	IC50 (µMol)	980.0000	0.0002	0.6603	10.0000	AID266249
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (6)

Process	via Protein(s)	Taxonomy
monoatomic ion transport	Solute carrier family 15 member 1	Homo sapiens (human)
protein transport	Solute carrier family 15 member 1	Homo sapiens (human)
peptide transport	Solute carrier family 15 member 1	Homo sapiens (human)
dipeptide import across plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
tripeptide import across plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
proton transmembrane transport	Solute carrier family 15 member 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (4)

Process	via Protein(s)	Taxonomy
proton-dependent oligopeptide secondary active transmembrane transporter activity	Solute carrier family 15 member 1	Homo sapiens (human)
peptide:proton symporter activity	Solute carrier family 15 member 1	Homo sapiens (human)
tripeptide transmembrane transporter activity	Solute carrier family 15 member 1	Homo sapiens (human)
dipeptide transmembrane transporter activity	Solute carrier family 15 member 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Process	via Protein(s)	Taxonomy
plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
brush border	Solute carrier family 15 member 1	Homo sapiens (human)
membrane	Solute carrier family 15 member 1	Homo sapiens (human)
apical plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
apical plasma membrane	Solute carrier family 15 member 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay ID	Title	Year	Journal	Article
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID266248	Ratio of %GSmax to EC50 for human PEPT1 activation	2006	Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12	Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID266246	Activation of human PEPT1 expressed in MDCK cells	2006	Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12	Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID266249	Binding affinity to human PEPT1 assessed as inhibition of [14C]Gly-Sar uptake in MDCK cells	2006	Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12	Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID266247	Activation of human PEPT1 expressed in MDCK cells relative to Gly-Sar	2006	Journal of medicinal chemistry, Jun-15, Volume: 49, Issue:12	Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (16.67)	18.7374
1990's	2 (33.33)	18.2507
2000's	2 (33.33)	29.6817
2010's	1 (16.67)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	12.60 (24.57)
Research Supply Index	1.95 (2.92)
Research Growth Index	4.55 (4.65)
Search Engine Demand Index	0.00 (26.88)
Search Engine Supply Index	0.00 (0.95)

This Compound (12.60)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
glycine [no description available]	2.03	1	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
valine Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.	2.03	1	L-alpha-amino acid zwitterion; L-alpha-amino acid; proteinogenic amino acid; pyruvate family amino acid; valine	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
glycyl-glycyl-glycine glycyl-glycyl-glycine : A tripeptide in which three glycine units are linked via peptide bonds in a linear sequence.	2.03	1	tripeptide zwitterion; tripeptide
glycylglycine [no description available]	2.03	1	dipeptide zwitterion; dipeptide	human metabolite
etoposide [no description available]	2.02	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
glucose, (beta-d)-isomer beta-D-glucose : D-Glucopyranose with beta configuration at the anomeric centre.. (1->4)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->4) linkages.. (1->3)-beta-D-glucan : A beta-D-glucan in which the glucose units are connected by (1->3) linkages.	1.98	1	D-glucopyranose	epitope; mouse metabolite
glycyl-glycyl-glycyl-glycine [no description available]	2.03	1
tyrosyltyrosine tyrosyltyrosine: RN given refers to all-(L)-isomer. tyrosyltyrosine : A dipeptide comprising tyrosine with a tyrosyl residue attached to the alpha-nitrogen.. Tyr-Tyr : Tyrosyltyrosine in which each tyrosine residue has L-configuration.	2.03	1	tyrosyltyrosine	Mycoplasma genitalium metabolite
leucylleucine Leu-Leu : A dipeptide formed from two L-leucine residues.	2.03	1	dipeptide; L-aminoacyl-L-amino acid zwitterion	human metabolite; Mycoplasma genitalium metabolite
phenylalanylphenylalanylamide [no description available]	2.03	1
Trp-Trp tryptophyltryptophan: an antigelation agent. Trp-Trp : A dipeptide formed from two L-tryptophan residues.	2.03	1	dipeptide	Mycoplasma genitalium metabolite
glycyltryptophan glycyltryptophan: RN given refers to (L)-isomer. Gly-Trp : A dipeptide formed from glycine and L-tryptophan residues.	2.03	1	dipeptide	metabolite
glycyltyrosine Gly-Tyr : A dipeptide composed of glycine and L-tyrosine joined by a peptide linkage.	2.03	1	dipeptide	metabolite
glycylleucine Gly-Leu : A dipeptide composed of glycine and L-leucine joined by a peptide linkage.	2.03	1	dipeptide zwitterion; dipeptide	metabolite
alanyltyrosine alanyltyrosine: tyrosine source; RN given refers to (L)-isomer. Ala-Tyr : A dipeptide composed of L-alanine and L-tyrosine joined by a peptide linkage.	2.03	1	dipeptide	metabolite
glycyl-l-phenylalanine glycylphenylalanine: RN given refers to (DL)-isomer. Gly-Phe : A dipeptide formed from glycine and L-phenylalanine residues.	2.03	1	dipeptide zwitterion; dipeptide	human metabolite; metabolite
glycylsarcosine glycylsarcosine : A dipeptide obtained by formal condensation of the carboxy group of glycine with the amino group of sarcosine.	2.03	1	dipeptide zwitterion; dipeptide
alanylphenylalanine alanylphenylalanine: RN given refers to (L-Ala-L-PheAla)-isomer	2.03	1	dipeptide	metabolite
tryptophylglycine Trp-Gly : A dipeptide formed from L-tryptophan and glycine residues.	2.03	1	dipeptide	metabolite
glycylaspartic acid glycylaspartic acid: RN given refers to (L)-isomer	2.03	1	dipeptide	metabolite
n-glycylglutamic acid N-glycylglutamic acid: RN given refers to (L)-isomer. Gly-Glu : A dipeptide formed from glycyl and L-glutamic acid residues.	2.03	1	dipeptide	metabolite
histidylglycine histidylglycine: RN given refers to all (L)-isomer. His-Gly : A dipeptide formed from L-histidine and glycine residues.	2.03	1	dipeptide	metabolite
valylvaline valylvaline: RN given refers to (L)-isomer. Val-Val : A dipeptide formed from two L-valine residues.	2.03	1	dipeptide	Mycoplasma genitalium metabolite
lysyllysine lysyllysine: RN given refers to (L-Lys)-isomer. Lys-Lys : A dipeptide formed from two L-lysine residues.	2.03	1	dipeptide	Mycoplasma genitalium metabolite
aspartylglycine Asp-Gly : A dipeptide composed of L-aspartic acid and glycine joined by a peptide linkage.	2.03	1	dipeptide	metabolite
arginylarginine Arg-Arg : A dipeptide formed from two L-arginine residues.	2.03	1	dipeptide	Mycoplasma genitalium metabolite
n-valyltryptophan N-valyltryptophan: RN given refers to (L)-isomer	2.03	1	peptide
prolylglutamic acid Pro-Glu : A dipeptide formed from L-proline and L-glutamic acid residues.	2.03	1	dipeptide	metabolite
glutamyl-glutamic acid glutamyl-glutamic acid: RN given for (L,L)-isomer. Glu-Glu : A dipeptide composed of two L-glutamic acid units joined by a peptide linkage.	2.03	1	dipeptide	Mycoplasma genitalium metabolite
aspartyl-aspartic acid aspartyl-aspartic acid: do not confuse with cyclo(Asp-Asp). Asp-Asp : A dipeptide formed from two L-aspartic acid units.	2.03	1	dipeptide	Mycoplasma genitalium metabolite
n-glycylalanine Gly-Ala : A dipeptide formed from glycine and L-alanine residues.	2.03	1	dipeptide	metabolite
glycylproline Gly-Pro : A dipeptide consisting of L-proline having a glycyl residue attached to its alpha-amino group.	2.03	1	dipeptide zwitterion; dipeptide	metabolite
glycyllysine glycyllysine: RN given refers to (L)-isomer. Gly-Lys : A dipeptide formed from glycine and L-lysine residues.	2.03	1	dipeptide	metabolite
alanylalanine L-alanyl-L-alanine : A dipeptide consisting of two L-alanine units joined by a peptide linkage.	2.03	1	dipeptide zwitterion; dipeptide	Mycoplasma genitalium metabolite
phenylalanylalanine phenylalanylalanine: RN given refers to (L)-isomer. Phe-Ala : A dipeptide formed from L-phenylalanine and L-alanine residues.	2.03	1	dipeptide zwitterion; dipeptide	metabolite
alanyltyrosine Tyr-Ala : A dipeptide formed from L-tyrosine and L-alanine residues.	2.03	1	dipeptide	metabolite
prolylglycine prolylglycine: RN given refers to (L)-isomer. L-prolylglycine : A dipeptide consisting of glycine having an L-prolyl group attached to its alpha-amino nitrogen.	2.03	1	dipeptide zwitterion; dipeptide
arginyllysine Arg-Lys : A dipeptide formed from L-arginyl and L-leucine residues.	2.03	1	dipeptide	metabolite
phenylalanylglycine phenylalanylglycine: RN given refers to (DL)-isomer. Phe-Gly : A dipeptide formed from L-phenylalanine and glycine residues.	2.03	1	dipeptide	metabolite
histidylhistidine histidylhistidine: RN given for L-,L-isomer	2.03	1	dipeptide	Mycoplasma genitalium metabolite
lysylglutamic acid lysylglutamic acid: a geroprotective agent. Lys-Glu : A dipeptide formed from L-lysine and L-glutamic acid residues.	2.03	1	dipeptide	metabolite
Ala-Lys Ala-Lys : A dipeptide obtained by formal condensation of the carboxy group of L-alanine with the alpha-amino group of L-lysine.	2.03	1	dipeptide	marine metabolite
valyl-valyl-valine [no description available]	2.03	1	peptide
lysylglycine lysylglycine: structure in first source. Lys-Gly : A dipeptide formed from L-lysine and glycine residues.	2.03	1	dipeptide	metabolite
glycylhistidine glycylhistidine: RN given refers to (L)-isomer. Gly-His : A dipeptide composed of glycine and L-histidine joined by a peptide linkage.	2.03	1	dipeptide zwitterion; dipeptide	metabolite
prolyl-serine Pro-Ser : A dipeptide formed from L-proline and L-serine residues.	2.03	1	dipeptide	metabolite
prolyl-proline Pro-Pro : A dipeptide formed from two L-proline residues.	2.03	1	dipeptide	human urinary metabolite; Mycoplasma genitalium metabolite

Condition	Indicated	Relationship Strength	Studies	Trials
Alopecia Cicatrisata [description not available]	0	2.02	1	0
Alopecia Absence of hair from areas where it is normally present.	0	2.02	1	0

chemdatabank.com